Distreptaza (streptokinase and streptodornase) rectal suppositories 15000ME+1250 IU №6


Manufacturer: Ukraine

Distreptaza used in the form of suppositories for insertion into the rectum. The dosage depends on the type and intensity of the inflammatory process. In severe disease in adults: 1 suppository 3 times a day for the first 3 days; 1 suppository 2 times a day for the next 3 days; 1 suppository 1 time per day for the next 3 days. With mild to moderate severity of the disease in adults: 1 suppository 2 times a day for 3 days; 1 suppository 1 time per day for the next 4 days; or 1 suppository 2 times a day for 2 days. On average, 8 to 18 suppositories are used for the course of treatment. The average duration of treatment is 7-10 days.



Distreptaza Storage
active substances: 1 suppository contains streptokinase 15 000 IU, streptodornase 1250 IU;

Distreptaza excipients: mineral oil, solid fat.

Distreptaza Dosage form
Rectal suppositories.

Main physical and chemical properties: the shape of cones or “torpedoes” with a pointed end; without mechanical damage with a color from white to cream.

Pharmacotherapeutic group
Antithrombotic drugs. Enzymes. ATX code B01A D.

Pharmacological properties


DISTREPTASE Distrept is a combination drug that contains two active substances – streptokinase and streptodornase. Streptokinase is an activator of the plasminogen proenzyme contained in human blood and under the influence of streptokinase is converted into plasmin, which has the ability to dissolve blood clots.

Streptodornase is an enzyme that has the ability to dissolve clusters of nucleoproteins, dead cells or pus, without affecting living cells and their physiological functions.

The drug facilitates the access of antibiotics or chemotherapeutic agents to the site of inflammation.


Not studied.

Treatment of chronic inflammatory processes of the uterine appendages, postoperative infiltrative lesions of the pelvic organs, endometritis, hemorrhoids in acute and chronic course, pararectal abscesses and fistulas with large inflammatory infiltrate, purulent caudal cysts.

The drug should not be used:

in case of hypersensitivity to the active or excipients that are part of the drug;
if the patient has fresh scab wounds or surgical sutures at the injection site: the medicine should not come into contact with a fresh scab wound or a recently sutured wound, as this may lead to weakening of the sutures and further bleeding from the wound;
after bleeding for about 10 days, as this may cause re-bleeding;
with drugs containing calcium salts;
with erysipelas;
patients with low blood clotting;
with anticoagulants (agents that reduce blood clotting) due to the increased risk of local bleeding.
Interaction with other medicinal products and other forms of interaction
Enhances the penetration of antibiotics, chemotherapeutic drugs into the site of inflammation. Contraindicated with anticoagulants, as bleeding at the injection site is possible.

Features of application
Use only on prescription. The drug may cause local irritation. Wash hands thoroughly before and after suppositories.

Use during pregnancy or breastfeeding.

Do not apply.

The ability to influence the speed of reaction when driving a car or other machinery.

Does not affect.